This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/7958585.stm
The article has changed 4 times. There is an RSS feed of changes available.
Version 2 | Version 3 |
---|---|
UK lagging on cancer care success | UK lagging on cancer care success |
(about 2 hours later) | |
The UK's track record of treating and curing cancer lags behind much of Europe, research shows. | The UK's track record of treating and curing cancer lags behind much of Europe, research shows. |
Data from the EUROCARE 4 project for 1988 to 1999 found lower complete cure rates in England and Scotland than countries such as Italy and Spain. | |
Long-term survival rate data also placed the UK below the European average - for some cancers significantly so. | |
Experts said cure and survival rates in the UK had improved since the study. | |
MALE CANCER CURE RATE Iceland: 46.6%Switzerland: 39.9%Italy: 37.0%Spain: 36.3%England: 34.5%France: 32.6%Scotland: 30.8%Czech Republic: 26.6%Slovenia: 23.7%Poland: 21.3% Figures for patients diagnosed, 1988-1999 | |
For all cancers combined, 34.5% of men, and 49.8% of women in England were cured between 1988 and 1999. In Scotland, the figures were 30.8% for men, and 44.8% for women. | |
For men Iceland topped the list with a 47% cure rate, while in France and Finland 59% of women were cured. | For men Iceland topped the list with a 47% cure rate, while in France and Finland 59% of women were cured. |
Eastern European countries had the worst track record, with Poland recording the worst cure rate for both men (21%) and women (38%). | Eastern European countries had the worst track record, with Poland recording the worst cure rate for both men (21%) and women (38%). |
Cure was defined as having a life expectancy no longer any different to that of the general population. | |
Examining five-year survival rates up to 2004, the UK was below the general European average, and more than 5% below the average for cancers of the stomach, ovary, prostate, thyroid and kidney. | Examining five-year survival rates up to 2004, the UK was below the general European average, and more than 5% below the average for cancers of the stomach, ovary, prostate, thyroid and kidney. |
However, it performed better than average for cancers of the head, neck and larynx, malignant melanoma and testicular cancer. | However, it performed better than average for cancers of the head, neck and larynx, malignant melanoma and testicular cancer. |
Professor Michel Coleman, from the London School of Hygiene and Tropical Medicine, said the UK's relatively poor showing was probably tied to a relative lack of investment in cancer services. | Professor Michel Coleman, from the London School of Hygiene and Tropical Medicine, said the UK's relatively poor showing was probably tied to a relative lack of investment in cancer services. |
He said at the time of the study, UK investment was 6-7% of GDP (Gross Domestic Product), compared to 9-11% on in many mainland European countries. | He said at the time of the study, UK investment was 6-7% of GDP (Gross Domestic Product), compared to 9-11% on in many mainland European countries. |
However, he said increased investment in recent years should soon start to see an improvement. | However, he said increased investment in recent years should soon start to see an improvement. |
Dr Lesley Walker, of the charity Cancer Research UK, warned that shortcomings in data collection made it impossible to make direct comparisons between different countries. | Dr Lesley Walker, of the charity Cancer Research UK, warned that shortcomings in data collection made it impossible to make direct comparisons between different countries. |
She also stressed that the data pre-dated the introduction of the Cancer Plan in England in 2000, which had led to improvements in treatment. | She also stressed that the data pre-dated the introduction of the Cancer Plan in England in 2000, which had led to improvements in treatment. |
Figures published last week suggested the plan has led to some improvement in survival rates. | Figures published last week suggested the plan has led to some improvement in survival rates. |
"The early diagnosis and treatment of cancer patients does vary between the UK and other European countries, but the degree of these differences and why they exist remains uncertain. | "The early diagnosis and treatment of cancer patients does vary between the UK and other European countries, but the degree of these differences and why they exist remains uncertain. |
"So we need to look closely at which areas we are lagging behind in and work out why." | "So we need to look closely at which areas we are lagging behind in and work out why." |
Professor Mike Richards, the government's cancer tsar, said it was key that people sought medical help quickly if they suspected something was wrong. | Professor Mike Richards, the government's cancer tsar, said it was key that people sought medical help quickly if they suspected something was wrong. |
Specific cancers | Specific cancers |
The EUROCARE study also found big variations across Europe for cure rates for specific cancers. | |
FEMALE CANCER CURE RATE France: 58.6%Finland: 58.0%Sweden: 56.1%Spain: 55.8%Italy: 54.4%England: 49.8%Czech Republic: 47.3%Slovenia: 44.9%Scotland: 44.8%Poland: 38.0% Figures for patients diagnosed, 1988-1999 | |
In France and Spain more than 10% of lung cancer patients were cured, but in Denmark, Czech Republic and Poland the figure was less than 5%. | |
Cure rates for prostate cancer ranged from more than 60% in France to only 14% in Denmark. | Cure rates for prostate cancer ranged from more than 60% in France to only 14% in Denmark. |
And for breast cancer, the cure rate was about 73% in Finland, Spain and Sweden, but only 60% in the Czech Republic, Poland and Slovenia. | And for breast cancer, the cure rate was about 73% in Finland, Spain and Sweden, but only 60% in the Czech Republic, Poland and Slovenia. |
Experts put the disparity in prostate and breast cancer cure rates down to differences in screening policy. | Experts put the disparity in prostate and breast cancer cure rates down to differences in screening policy. |
The EUROCARE study also compared cure rates for patients diagnosed in 1988-1990 with those from 1997-1999 across 23 countries. | |
Cure rates rose across the board, with bowel cancer up from 42% to 49%, stomach cancer up from 15% to 18% and lung cancer up from 6% to 8%. | Cure rates rose across the board, with bowel cancer up from 42% to 49%, stomach cancer up from 15% to 18% and lung cancer up from 6% to 8%. |
Age and sex differences | Age and sex differences |
Data from the study also shows that survival rates among elderly people (aged over 70) were lower than those among middle-aged patients (55-69 years), with the gap widening. | Data from the study also shows that survival rates among elderly people (aged over 70) were lower than those among middle-aged patients (55-69 years), with the gap widening. |
Experts said this could be due to cancer being picked up at a more advanced stage in the elderly. | Experts said this could be due to cancer being picked up at a more advanced stage in the elderly. |
Women with cancer had a longer life expectancy than men for 21 out of 26 types of the disease. | Women with cancer had a longer life expectancy than men for 21 out of 26 types of the disease. |
Overall, women had a 52% chance of surviving cancer for at least five years, compared to 50% for men, with the gap narrowing among older people. | Overall, women had a 52% chance of surviving cancer for at least five years, compared to 50% for men, with the gap narrowing among older people. |
The researchers said differences in sex hormone patterns may play a key role in this gender difference. | The researchers said differences in sex hormone patterns may play a key role in this gender difference. |
The five-year survival rate was 81% for children aged up to 14 years, and 87% among the 15-24 age group, with the chances of dying within five years of diagnosis falling significantly in recent years. |